| Name | Title | Contact Details |
|---|
Headquartered in Roxboro, N.C., Open Book Extracts is a cGMP-certified manufacturer of premium plant-based cannabinoid products, aiming to be the industry`s true north by delivering premium products, exceptional service, and industry-leading transparency. With control of the entire supply chain, a state-of-the-art extraction campus near North Carolina`s Research Triangle, proprietary refinement and conversion methods backed by a growing IP portfolio, and a team of PhD chemists and seasoned business leaders, OBX is the trusted partner for global brands seeking to enter the marketplace. OBX Asia, with its headquarters in Hong Kong, provides strategic guidance and on-the-ground support for our Asia customers. OBX`s cGMP-certified productions operations are led by a seasoned science team, including a PhD food scientist from Cornell, a PhD organic chemist from the University of Nevada, and two masters chemists with pharmaceutical backgrounds, including a quality control director who joined OBX after a 15-year career as an analytical chemist at GlaxoSmithKline. OBX offers one of the largest portfolios of cannabinoid isolates at 99%+ purity, including CBD, CBG, CBN, CBC, and THCV, as well as formulation services and turnkey finished good manufacturing including edibles, softgels, tablets, tinctures, pet products, and topical products.
Scryptions International is a Henderson, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.
Synergy Vision is a Livermore, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advanced Imaging Technologies is a Richland, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.